The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Oxford BioDynamics Demonstrates Use Of EpiSwitch In Lymphoma Detection

Wed, 15th Jan 2020 15:17

(Alliance News) - Oxford BioDynamics PLC on Wednesday said it has conducted a study proving its EpiSwitch biomarkers can successfully detect lymphoma in dogs.

The study - which focused on the diagnosis of B-cell lymphoma in dogs - saw Oxford Biodynamics generate a new biomarker signature using blood from a group of dogs with lymphoma and validate it using a second group of dogs without lymphoma, in an attempt to see if the dogs with lymphoma could correctly be identified.

The newly-generated biomarker signature was able to correctly identify dogs with and without lymphoma with 80% in accuracy, sensitivity, specificity, positive predictive value and negative predictive value.

The results of the study proved that EpiSwitch biomarkers can be "successfully translated across species for related pathologies and conditions," the biotechnology company said, adding that it highlighted the potential application of non-invasive EpiSwitch biomarkers in new therapeutic developments, including within the veterinary industry.

"Our EpiSwitch technology has provided us with a great wealth of data associated with lymphoma patients, and subsequently allowed us to translate these insights into canines, where there is a well-recognised unmet need. It is clear that the fundamentals of 3D genomics open up a new dimension for the application of EpiSwitch, particularly in veterinary science and animal welfare," said Oxford BioDynamics's Chief Scientific Officer Alexandre Akoulitchev.

"Whilst we remain focused on human health, this study demonstrates that there is a wider potential of our technology to ensure that the benefit of EpiSwitch is fully realised," he added.

Oxford Biodynamics has already signed several deals to identify biomarkers in the diagnosis of different conditions including autism, prostate cancer and amyotrophic lateral sclerosis.

Shares in the company were up 1.3% at 114.50 pence each on Wednesday afternoon in London.

By Ife Taiwo; ifetaiwo@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Related Shares

More News
23 May 2024 21:08

TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

21 May 2024 14:06

Oxford BioDynamics to provide tests to largest UK charitable hospital

(Alliance News) - Oxford BioDynamics PLC on Tuesday announced a new partnership with The London Clinic.

16 May 2024 20:09

TRADING UPDATES: Bens Creek considers administration; Nexxen inks deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

3 Apr 2024 14:31

Oxford BioDynamics reaches "important milestone" with new laboratory

(Alliance News) - Oxford BioDynamics PLC said on Wednesday that it has opened a clinical testing laboratory in the UK to perform EpiSwitch prostate sc...

14 Mar 2024 16:53

TRADING UPDATES: FireAngel CFO resigns; ECR Minerals raises GBP585,000

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.